Aclaris Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
32.50
|
|
Average Rating
|
4.67
|
|
# Strong Buys
|
6
|
|
# Buys
|
3
|
|
# Holds
|
0
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.40
|
-0.30
|
0.10
|
25.00%
|
|
2022-06-30
|
-0.36
|
-0.31
|
0.05
|
13.89%
|
|
2022-03-31
|
-0.40
|
-0.31
|
0.09
|
22.50%
|
|
2021-12-31
|
-0.36
|
-0.37
|
-0.01
|
-2.78%
|
|
2021-09-30
|
-0.28
|
-0.35
|
-0.07
|
-25.00%
|
|
2021-06-30
|
-0.28
|
-0.34
|
-0.06
|
-21.43%
|
|
2021-03-31
|
-0.29
|
-0.57
|
-0.28
|
-96.55%
|
|
2020-12-31
|
-0.27
|
-0.30
|
-0.03
|
-11.11%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-0.92
|
|
2021-12-31
|
-1.63
|
|
2020-12-31
|
-1.20
|
|
2019-12-31
|
-3.91
|
|
2018-12-31
|
-4.04
|
|
2017-12-31
|
-2.41
|
|
2016-12-31
|
-2.26
|
|
2015-12-31
|
-5.39
|